{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T03:58:54Z","timestamp":1754107134223,"version":"3.37.3"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,27]],"date-time":"2021-12-27T00:00:00Z","timestamp":1640563200000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Drug reaction with eosinophilia and systemic symptoms syndrome is a rare but severe and potentially life-threatening hypersensitivity reaction, with significant morbidity and mortality. The clinical presentation of drug reaction with eosinophilia and systemic symptoms may include extensive skin rash, fever, lymphadenopathy, internal organ involvement, eosinophilia, and atypical lymphocytosis, most commonly due to drug-induced reaction. Our case is a rare occurrence of drug reaction with eosinophilia and systemic symptoms syndrome in the setting of oxacillin therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 55-year-old Caucasian male presented to the emergency department on account of acute onset, 2-day history of generalized pruritic rash with associated fever, occurring 3\u00a0weeks after commencing therapy with intravenous oxacillin for methicillin-sensitive <jats:italic>Staphylococcus\u00a0aureus<\/jats:italic> bacteremia. He had no known drug allergies. Two\u00a0days prior to hospitalization, he had a telehealth visit with the infectious diseases specialist on account of his rash, and was recommended to use oral diphenhydramine. However, with the onset of fever and persistence of his rash, he was advised to discontinue the oxacillin and present to the emergency department. On examination, he was febrile at 101.2\u00a0\u00b0F and had a generalized blanchable maculopapular and morbilliform rash involving the face, trunk, upper and lower extremities, but sparing the palms, soles, and oral mucosa. He had palpable nontender lymph nodes in the cervical and inguinal regions bilaterally. Laboratory studies revealed atypical lymphocytosis, eosinophilia, neutrophilia, and elevated serum transaminases. He was started on intravenous diphenhydramine and admitted to the in-patient medical service. On the second day of hospitalization, his fever resolved. However, his rash was persistent and generalized, as well as elevated transaminases and an abnormal cell count on the second day of hospitalization. To complete his 6-week course of antibiotics for methicillin-sensitive <jats:italic>Staphylococcus\u00a0aureus<\/jats:italic> bacteremia, he was switched to an alternative therapy with cefazolin, and he was scheduled for weekly follow-up assessments following hospital discharge.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Healthcare providers should increasingly be aware of the significant morbidity and mortality attributable to drug reaction with eosinophilia and systemic symptoms syndrome and the potential medications which may incite such life-threatening reactions. Early recognition of drug reaction with eosinophilia and systemic symptoms syndrome and prompt institution of management strategies can promote improved clinical outcomes. Enhanced patient\u2013provider communication strategies should be implemented to better prepare patients for the likelihood of such drug reactions, with the goal of improving patient-centered care and adherence with treatment strategies.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13256-021-03202-9","type":"journal-article","created":{"date-parts":[[2021,12,27]],"date-time":"2021-12-27T00:02:41Z","timestamp":1640563361000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["DRESS syndrome in the setting of oxacillin therapy\u2014a call for better patient preparedness: a case report"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9359-7373","authenticated-orcid":false,"given":"Hawa Ozien","family":"Abu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sajjadh M. J.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anil","family":"Phuyal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akil","family":"Sherif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory T.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iryna","family":"Chastain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,12,27]]},"reference":[{"key":"3202_CR1","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/S1085-5629(96)80038-1","volume":"15","author":"H Bocquet","year":"1996","unstructured":"Bocquet H, Bagot M, Roujeau JC. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). Semin Cutan Med Surg. 1996;15:250\u20137.","journal-title":"Semin Cutan Med Surg"},{"key":"3202_CR2","doi-asserted-by":"publisher","first-page":"479","DOI":"10.4103\/2249-4863.192366","volume":"5","author":"A Jmeian","year":"2016","unstructured":"Jmeian A, Hawatmeh A, Shamoon R, Shamoon F, Guma M. Skin rash, eosinophilia, and renalimpairment in a patient recently started on allopurinol. J Family Med Prim Care. 2016;5:479\u201381.","journal-title":"J Family Med Prim Care."},{"issue":"6","key":"3202_CR3","first-page":"31","volume":"6","author":"S Choudhary","year":"2013","unstructured":"Choudhary S, McLeod M, Torchia D, Romanelli P. Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. J Clin Aesthet Dermatol. 2013;6(6):31\u20137.","journal-title":"J Clin Aesthet Dermatol."},{"key":"3202_CR4","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1752-1947-7-2","volume":"7","author":"Hall and Fromm","year":"2013","unstructured":"Hall and Fromm. Drug reaction with eosinophilia and systemic symptoms syndrome in a patient taking phenytoin and levetiracetam: a case report. J Med Case Reports. 2013;7:2.","journal-title":"J Med Case Reports"},{"issue":"1","key":"3202_CR5","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1159\/000487670","volume":"176","author":"ST H\u00fcbner","year":"2018","unstructured":"H\u00fcbner ST, Bertoli R, R\u00e4tz Bravo AE, et\u00a0al. C-reactive protein and procalcitonin in case reports of drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. Int Arch Allergy Immunol. 2018;176(1):44\u201354.","journal-title":"Int Arch Allergy Immunol"},{"issue":"12","key":"3202_CR6","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s40264-015-0343-3","volume":"38","author":"F Renda","year":"2015","unstructured":"Renda F, Landoni G, Bertini Malgarini R, et\u00a0al. Drug reaction with eosinophilia and systemic symptoms (DRESS): a national analysis of data from 10-year post-marketing surveillance. Drug Saf. 2015;38(12):1211\u20138.","journal-title":"Drug Saf"},{"key":"3202_CR7","doi-asserted-by":"publisher","first-page":"345","DOI":"10.12659\/AJCR.913748","volume":"20","author":"A Sharpe","year":"2019","unstructured":"Sharpe A, Mourad BM, Hardwick CJ, Reilly T, Dweck E, Bondarsky E. Oxacillin-induced drug reaction with eosinophilia and systemic symptoms (DRESS). Am J Case Rep. 2019;20:345\u20138.","journal-title":"Am J Case Rep."},{"issue":"1","key":"3202_CR8","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.arcped.2014.08.021","volume":"22","author":"A Rabenkogo","year":"2015","unstructured":"Rabenkogo A, Vigue MG, Jeziorski E. DRESS syndrome. Arch Pediatr. 2015;22(1):57\u201362 (in French).","journal-title":"Arch Pediatr"},{"issue":"5","key":"3202_CR9","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1111\/bjd.12501","volume":"169","author":"SH Kardaun","year":"2013","unstructured":"Kardaun SH, Sekula P, Valeyrie-Allanore L, et\u00a0al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol. 2013;169(5):1071\u201380.","journal-title":"Br J Dermatol"},{"key":"3202_CR10","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.annder.2010.04.024","volume":"137","author":"V Descamps","year":"2010","unstructured":"Descamps V, Ben-Sa\u00efd B, Sassolas B, Truchetet F, Avenel-Audran M, Girardin P, Guinnepain MT, Mathelier-Fusade P, Assier H, Milpied B, Modiano P, Lebrun-Vignes B, Barbaud A. Groupe Toxidermies de la Soci\u00e9t\u00e9 fran\u00e7aise de dermatologie: management of drug reaction with eosinophilia and systemic symptoms (DRESS). Ann Dermatol Venereol. 2010;137:703\u20138.","journal-title":"Ann Dermatol Venereol"},{"key":"3202_CR11","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1590\/S0365-05962012000300013","volume":"87","author":"PR Criado","year":"2012","unstructured":"Criado PR, Criado RF, Avancini JM, Santi CG. Drug reaction with eosinophilia and systemic symptoms (DRESS)\/drug-induced hypersensitivity syndrome (DIHS): a review of current concepts. An Bras Dermatol. 2012;87:435\u201349.","journal-title":"An Bras Dermatol"},{"issue":"4","key":"3202_CR12","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1159\/000069956","volume":"206","author":"S Tas","year":"2003","unstructured":"Tas S, Simonart T. Management of drug rash with eosinophilia and systemic symptoms (DRESS syndrome): an update. Dermatology. 2003;206(4):353\u20136.","journal-title":"Dermatology"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-021-03202-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-021-03202-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-021-03202-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,27]],"date-time":"2021-12-27T00:03:06Z","timestamp":1640563386000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-021-03202-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["3202"],"URL":"https:\/\/doi.org\/10.1186\/s13256-021-03202-9","relation":{},"ISSN":["1752-1947"],"issn-type":[{"type":"electronic","value":"1752-1947"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"25 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed verbal and written consent was obtained from the patient. All specific identifying information regarding the patient were de-identified. This case report did not include any new or experimental treatment different from the current guidelines for the management of DRESS syndrome, hence approval from an ethics committee was not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"613"}}